D-Serine in Neuropsychiatric Disorders: New Advances

Figure 5

Effect of NMDAR-glycine-site agonists on dyskinesia symptoms as reflected in Abnormal Involuntary Movement Scale (AIMS) score. Data are from studies of glycine [61, 64] and D-serine [62, 65]. Across all studies, D-serine treatment led to a highly significant (𝑡 = 4.86, d.f. = 192, 𝑃<0.00001, d = 0.83) improvement in AIMS scores. (Reproduced from [66]).

(a)

(b)